New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
07:41 EDTSNYSanofi R&D focused on biology of disease, WSJ reports
Dr. Elias Zerhouni, a former director of the U.S. National Institutes of Health, and now head of R&D at Sanofi (SNY) is attempting to shift to an earlier stage of research and development, and boost the number and quality of the company's drug discoveries. He has recruited about 20 new R&D leaders to help Sanofi become better at understanding how diseases work and how to target them. "We're investing a lot more upstream in understanding human-disease biology," he says. "We're extremely good at toolmaking," he added, referring to the formulation of new pills and shots, "but not very good at understanding the biology" of disease.Reference Link
News For SNY From The Last 14 Days
Check below for free stories on SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
September 11, 2014
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
September 3, 2014
12:49 EDTSNYSanofi reports Dengue vaccine candidate achieves its phase 3 primary endpoint
Sanofi Pasteur, the vaccines division of Sanofi, announced that the final landmark phase 3 efficacy study of its dengue vaccine candidate in Latin America successfully achieved its primary clinical endpoint. Results showed an overall significant reduction of 60.8% of dengue disease cases in children and adolescents 9-16 years old after a three-dose vaccination schedule. Importantly, efficacy was observed against each of the four dengue serotypes. Additional observations of the results showed a clinically important reduction by 80.3% in the risk of hospitalization due to dengue during the study. The results also showed in the study population an efficacy against dengue haemorrhagic fever, the severe form of dengue, which is consistent with the results released from Sanofiís phase 3 dengue study in Asia. Lastly, the results suggest better protection in case of prior exposure to dengue.
September 2, 2014
20:26 EDTSNYSanofi has a conference call hosted by JPMorgan
Subscribe for More Information
13:58 EDTSNYRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
08:35 EDTSNYIntrexon enters into ECC with Sanofi subsidiary to develop APIs
Subscribe for More Information
07:21 EDTSNYRegeneron data positive, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use